Baird Upgrades Theravance Biopharma to Neutral, Lowers Price Target to $18

Baird upgrades Theravance Biopharma (NASDAQ:TBPH) from Underperform to Neutral and lowers the price target from $22 to $18.

Benzinga · 11/06/2019 11:37

Baird upgrades Theravance Biopharma (NASDAQ:TBPH) from Underperform to Neutral and lowers the price target from $22 to $18.